Shares of Omnicell, Inc. (NASDAQ:OMCL) have earned an average recommendation of “Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $55.14.

A number of research analysts recently commented on OMCL shares. Cantor Fitzgerald boosted their price target on Omnicell to $58.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Benchmark boosted their price target on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. Zacks Investment Research cut Omnicell from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 1st. Oppenheimer reissued a “buy” rating and issued a $55.00 price target on shares of Omnicell in a report on Thursday, October 19th. Finally, Craig Hallum reissued a “buy” rating and issued a $62.00 price target (up from $52.00) on shares of Omnicell in a report on Monday, October 30th.

In other news, VP Peter J. Kuipers sold 3,532 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $50.96, for a total transaction of $179,990.72. Following the sale, the vice president now directly owns 40,714 shares of the company’s stock, valued at approximately $2,074,785.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Dan S. Johnston sold 14,613 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $47.81, for a total value of $698,647.53. Following the sale, the executive vice president now directly owns 43,621 shares in the company, valued at $2,085,520.01. The disclosure for this sale can be found here. Insiders have sold a total of 38,944 shares of company stock worth $1,889,592 over the last ninety days. Insiders own 3.77% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in OMCL. Aperio Group LLC raised its holdings in Omnicell by 84.7% during the 2nd quarter. Aperio Group LLC now owns 29,730 shares of the company’s stock valued at $1,281,000 after buying an additional 13,637 shares during the period. Municipal Employees Retirement System of Michigan raised its holdings in Omnicell by 5.3% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,780 shares of the company’s stock valued at $378,000 after buying an additional 440 shares during the period. Great West Life Assurance Co. Can raised its holdings in Omnicell by 3.2% during the 2nd quarter. Great West Life Assurance Co. Can now owns 54,840 shares of the company’s stock valued at $2,358,000 after buying an additional 1,680 shares during the period. Texas Permanent School Fund raised its holdings in Omnicell by 1.4% during the 2nd quarter. Texas Permanent School Fund now owns 27,134 shares of the company’s stock valued at $1,169,000 after buying an additional 378 shares during the period. Finally, Sei Investments Co. raised its holdings in Omnicell by 36.4% during the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock valued at $200,000 after buying an additional 1,242 shares during the period. Institutional investors own 99.85% of the company’s stock.

Omnicell (NASDAQ OMCL) traded up $0.10 during midday trading on Monday, reaching $51.05. The company had a trading volume of 207,100 shares, compared to its average volume of 255,770. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.08 and a current ratio of 1.53. Omnicell has a one year low of $31.85 and a one year high of $55.40.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.42 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The company had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same period in the previous year, the firm earned $0.40 EPS. The firm’s revenue was up 5.7% compared to the same quarter last year. equities analysts forecast that Omnicell will post 0.12 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/11/omnicell-inc-omcl-given-consensus-recommendation-of-buy-by-analysts.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.